J3300 HCPCS code: Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
J3300 is the HCPCS Level II code for injection, triamcinolone acetonide (triesence), preservative free, 1 mg. In 2024 Medicare paid an average of $3.54 per service for J3300 across 798,270 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 80 per day on outpatient hospital claims. Medicare volume fell 63% from 2022 to 2024 (2,154,478 to 798,270 services). In 2024, about 595 clinicians billed Medicare for J3300 for 11,356 beneficiaries; Virginia, Florida, New Jersey accounted for 59% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2009-01-01 |
| Last action effective | 2026-10-01 |
Who bills J3300 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 595 |
| Medicare beneficiaries | 11,356 |
| States with claims | 31 |
| Share of services in top 3 states (Virginia, Florida, New Jersey) | 59% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3300, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,154,478 | 23,993 | $3.77 | $2.98 |
| 2023 | 1,202,707 | 19,741 | $3.97 | $3.13 |
| 2024 | 798,270 | 11,356 | $4.45 | $3.54 |
States with the most J3300 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Virginia | 173,436 | $0.58 |
| Florida | 152,196 | $5.85 |
| New Jersey | 147,896 | $3.98 |
| North Carolina | 59,264 | $0.45 |
| New York | 38,660 | $3.77 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 80 | CMS Policy |
| practitioner claims | 80 | CMS Policy |
Medicare policy articles for this code
- A57114: Billing and Coding: Trigger Point Injections (First Coast Service Options, Inc. (MAC - Part B))
- A57751: Billing and Coding: Trigger Point Injections (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B))
Covered diagnoses (2 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| M79.12 | Myalgia of auxiliary muscles, head and neck | 2 |
| M79.18 | Myalgia, other site | 2 |
What changed for J3300
- October 2026: Descriptor revised (Was: Injection, triamcinolone acetonide, preservative free, 1 mg)
- 2026-10-01: Last CMS action: long description changed
- 2009-01-01: J3300 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3300?
J3300 is the HCPCS Level II code for injection, triamcinolone acetonide (triesence), preservative free, 1 mg. Short descriptor: "Triamcinolone a inj prs-free".
How much does Medicare pay for J3300?
In 2024, the average Medicare payment was $3.54 per service (average allowed $4.45).
Does Medicare cover J3300?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Which diagnoses support coverage for J3300?
Medicare policy articles that cite J3300 list 2 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include M79.12 (Myalgia of auxiliary muscles, head and neck), M79.18 (Myalgia, other site). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J3300 can be billed per day?
80 on outpatient hospital claims; 80 on practitioner claims (NCCI medically unlikely edits).
Related J33 codes
- J3301 — Injection, triamcinolone acetonide, not otherwise specified, 10 mg
- J3302 — Injection, triamcinolone diacetate, per 5 mg
- J3303 — Injection, triamcinolone hexacetonide, per 5 mg
- J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3305 — Injection, trimetrexate glucuronate, per 25 mg
- J3310 — Injection, perphenazine, up to 5 mg
- J3315 — Injection, triptorelin pamoate, 3.75 mg
- J3316 — Injection, triptorelin, extended-release, 3.75 mg
- J3320 — Injection, spectinomycin dihydrochloride, up to 2 gm
- J3350 — Injection, urea, up to 40 gm
- J3355 — Injection, urofollitropin, 75 iu
- J3357 — Ustekinumab, for subcutaneous injection, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3300
- Watch J3300 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3300
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.